The Mays Cancer Center at UT Health San Antonio and Evestra Inc., a San Antonio-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from NIH for the research and development of a drug targeting ovarian cancer, EC359. It is the first grant of this kind awarded to The University of Texas Health Science Center at San Antonio.
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...
